And if you sold $abvx because of this instead of buying then you never should have been invested in the first place
1
10
823
Wow. Feels like short $sls was the most consensus biox play in a while
2
6
1,652
This is either an amazing joke, or an absolutely insane lack of awareness #vyera
1
5
5,827
Of all the stupid shit and bs theories about $abvx this one is the runaway favorite for dumbest of them all
$ABVX Personally, I have no doubt Ricks’s post yesterday was aimed at ABVX. My read: frustration over price may be boiling over—and BioX, more specifically Adam May’s analysis, could be the reason.
My theory is that Marc and the board are reading the same analysis that brought many of us to ABVX, and it’s giving them confidence to demand a higher price. I’d even speculate that Adam’s valuation work is more in-depth than what ABVX has developed internally. And if you’re misspelling your own drug’s name, perhaps the detailed analysis being shared on X deserves a closer look.
Adam's posts could be strengthening the board’s conviction about what obefazimod is worth while making a lower offer harder to justify to shareholders. I suspect that without Adam helping shape those expectations, an offer might already have been accepted.
If Lilly is trying to acquire ABVX on the cheap, BioX—and Adam’s analysis in particular—certainly aren’t making it any easier. That could explain the frustration behind Ricks’ post.
5
26
3,450
While this gets me a little excited…how do we know this isn’t @unemon1 cosplaying as a trial participant $abvx
Well I guess it wasn't my final thought on $ABVX today.
Caveat emptor on Reddit alpha, but this account has been on the Crohn's beat for quite a while, claims to be on the Obe CD trial, and says they've had a *mega* response of SES from 27 to 0.
That's an objective, endoscopic (not patient reported) metric, and that's a HUGE response magnitude.
An SES score of 16 is the highest grading threshold, representing "severe" disease. In 12 weeks this patient (supposedly) went from almost twice that to *zero*. Complete endoscopic remission.
How big of a response would that be? Rinvoq's high dose on induction achieved a mean reduction of -6.8 at week 12, versus -0.5 on placebo. (source academic.oup.com/ecco-jcc/ar…)
So yes, -27 points on SES would be an outstanding response. Highly, highly, highly unlikely something of that magnitude could be placebo.
This CD trial is only ~50pts per arm, and is using a reduction from baseline (not responder threshold) based primary endpoint, btw...
4
35
5,511
Something something something fake index $xbi all my stocks are down
4
401
I’ll never be able to bring myself to sell this turd, so hopefully someone just buys this at $90 and I can move on $abvx
1
29
2,238
lol
Some news.
I've been thinking about this for a while, and coming out of summer I finally have the headspace to do it properly.
I'm launching a Substack. $30/month.
What you get:
•Full access to my portfolio, with position sizing
•The Weekly, every Tuesday
•Stock pitches and reviews
•Catalyst tracking
•Summaries of my conversations with management teams, buyside and sellside
•The personal side of the journey, wins and mistakes both
X will stay my place for discussion and I'm not going anywhere. But the actual work, the ideas and the commentary, moves to Substack.
Why charge? Two reasons.
First, I've always tried to go above and beyond for people who follow me and I'm grateful for the support. But the last few weeks have been rough. Fake accounts, harassment, worse than that in my DMs. I've got most of what I ever wanted and I've still not been happy, and that's down to a small handful of people. Putting this behind a paywall means I'm writing for the people who actually want to be there.
Second, and more importantly, charging a fee means I owe you consistency. No more sporadic posting when I feel like it. If you're paying, you're getting The Weekly every week and the work that goes with it.
On track record: I'm ahead of the XBI again this year and have beaten it every year since I started. The first Weekly on Tuesday will show YTD return and full position distribution so you can see it for yourself.
Housekeeping: the Abivax channel in the Discord moves to paid Substack subscribers only.
Link below:
open.substack.com/pub/seedy1…
35
2,315
I am calling bottom $abvx
I will also delete if this is, in fact, not the bottom.
That’s it? Do people actually think $mrna is going to be breakeven by 2028?








